AM Technical Solutions buys Sequence to deepen life sciences engineering
What's the deal? AM Technical SolutionsDealroom has a profile for this one. Try Dealroom → (AM) has acquired Sequence, Inc., a Morrisville, North Carolina engineering firm specialising in process design and commissioning, qualification, and validation (CQV) for life sciences clients. AM, founded in 1994, is a global architecture, engineering, construction, and commissioning firm serving high-tech markets. Terms were not disclosed.
What each side brings: Sequence offers expertise in CQV, computer system validation, IT/OT integration, and facility startup for pharmaceutical and biopharmaceutical clients. AM gains that team and its client relationships, extending its existing engineering and CQV bench.
What changes? Sequence will keep operating under its current leadership, backed by AM's global platform and project delivery network. The combined firm aims to offer clients a single point of accountability from project conception to product manufacturing.
Why it matters: "Their understanding of the overall manufacturing lifecycle . . . directly strengthens our ability to serve life sciences clients at every stage of a project," said Dave Watrous, chief executive officer of AM. Founder and chief executive officer Mike Putnam said joining AM gives Sequence "access to a global network of engineering and construction expertise."
What's the endgame? The deal deepens AM's bench with an established team and client base, rather than simply adding capacity. That distinction matters for winning complex capital projects in tightly regulated pharma and biopharma facilities.
The signal: The acquisition fits an ongoing wave of consolidation in specialised life sciences services, particularly around CQV for pharma facilities. Buyers increasingly want end-to-end offerings spanning facility design, commissioning, and validation — a differentiator in competing for large biopharma and advanced-therapy mandates.
Read more: Access Newswire
Image credit: USDAgov
